Confident of addressing 3 USFDA observations for Malaysia unit expeditiously, says Biocon
Updated : February 24, 2020 11:33 AM IST
In a position to launch insulin glargine in H2CY20 with Mylan.
Transition from NDA to BLA for certain biologics will not impact Co's submission.
Published : February 24, 2020 11:31 AM IST